News Focus
News Focus
Followers 17
Posts 1739
Boards Moderated 0
Alias Born 03/03/2014

Re: neophyte184 post# 51196

Wednesday, 12/09/2015 3:21:45 PM

Wednesday, December 09, 2015 3:21:45 PM

Post# of 63807

Not ones bringing in the kind of revenue that PXYN is. No.



Please. If PXYN does $50M in WC gross billings in Q4 they will factor for 18% or less. That's $9M, or which 13% / $6.5M (or 13.5% / $6.75M , I can't recall) goes to the sales referral agent.

That means that $200M in annual WC gross billings provides between $9M and $10M in net revenue. That MIGHT - or might not - cover PXYN's operating expenses. It certainly doesn't leave any room for profits.

A year ago PXYN estimated that 54% of WC gross billings was recoverable. As of Q3 it reduced that estimate to 30%. $50M in WC gross billings is currently worth less than $28M in WC gross billings from a year ago.

This compression is likely ongoing as insurance companies will likely continue to reduce their reimbursement levels for insanely-overpriced compounded medications - or stop covering them altogether.

There is a spiral here, and its two primary attributes are "downward" and "death".
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y